New Experimental Modalities in the Control of Neoplasia: NATO Science Series A:, cartea 120
Editat de Prakash Chandraen Limba Engleză Paperback – 12 dec 2012
Din seria NATO Science Series A:
- 15% Preț: 656.58 lei
- 15% Preț: 655.13 lei
- 15% Preț: 678.35 lei
- Preț: 397.38 lei
- 5% Preț: 377.87 lei
- Preț: 397.76 lei
- 18% Preț: 1232.41 lei
- 5% Preț: 731.64 lei
- Preț: 413.15 lei
- 15% Preț: 649.22 lei
- 5% Preț: 369.45 lei
- Preț: 407.56 lei
- 5% Preț: 2162.19 lei
- Preț: 407.39 lei
- Preț: 396.40 lei
- 15% Preț: 663.93 lei
- Preț: 387.38 lei
- Preț: 393.13 lei
- Preț: 398.35 lei
- Preț: 401.24 lei
- 15% Preț: 678.81 lei
- Preț: 395.09 lei
- 18% Preț: 952.40 lei
- 15% Preț: 654.43 lei
- Preț: 402.00 lei
- 15% Preț: 655.27 lei
- Preț: 394.71 lei
- Preț: 384.48 lei
- 5% Preț: 395.61 lei
- 5% Preț: 1421.57 lei
- 15% Preț: 651.34 lei
- Preț: 400.10 lei
- Preț: 386.99 lei
- 5% Preț: 386.11 lei
- Preț: 403.91 lei
- 15% Preț: 651.51 lei
- Preț: 393.90 lei
- 5% Preț: 376.43 lei
- Preț: 400.26 lei
- 5% Preț: 388.84 lei
- Preț: 400.65 lei
- 5% Preț: 740.58 lei
- 18% Preț: 1225.16 lei
- 5% Preț: 386.46 lei
- Preț: 421.82 lei
Preț: 401.24 lei
Nou
Puncte Express: 602
Preț estimativ în valută:
76.80€ • 79.14$ • 64.84£
76.80€ • 79.14$ • 64.84£
Carte tipărită la comandă
Livrare economică 04-18 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781468452440
ISBN-10: 1468452444
Pagini: 420
Ilustrații: XI, 402 p. 80 illus.
Dimensiuni: 178 x 254 x 22 mm
Greutate: 0.73 kg
Ediția:Softcover reprint of the original 1st ed. 1986
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
ISBN-10: 1468452444
Pagini: 420
Ilustrații: XI, 402 p. 80 illus.
Dimensiuni: 178 x 254 x 22 mm
Greutate: 0.73 kg
Ediția:Softcover reprint of the original 1st ed. 1986
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
1. A Developmental Biologist’s View of Cancer.- 2. Oncogenes in Development, Neoplasia and Evolution.- 3. Acquisition of Metastatic Properties via Somatic Cell Fusion: Implications for Tumor Progression in vivo.- 4. Oncogenes and Tyrosine Kinase Activities as a Function of the Metastatic Phenotype.- 5. Immune Reactivities During the Precancer and Early Cancer Periods: Novel Approaches for Immunomodulation.- 6. Immunomodulation of Tumor Metastases.- 7. Monoclonal Antibody Targeting of Anti-Cancer Agents.- 8. Treatment of Human B Cell Lymphoma with Monoclonal Anti-Idiotype Antiboaies.- 9. Human Monoclonal Antibodies Directed Against HuMTV Antigens form Human Breast Cancer Cells.- 10. Recent Advances in Thymic Hormone Research.- 11. T-Cell Growth Factor (Interleukin -2).- 12. Drug Resistance: New Approaches to Treatment.- 13. Mechanisms of Membrane-Mediated Cytotoxicity by Adriamycin.- 14. Terminal Transferase and Adenosine Deaminase Activities in Human Neoplasia: Their Role in Modulating Cancer Treatment.- 15. Inhibitors of Terminal Transerase: A New Strategy for the Treatment of Human Leukemia.- 16. DNA-Protein Crosslinking of Platinum Coordination Complex in Living Cells: Implication to Evaluate the Cytotoxic Effects of Chemotherapeutic Agents.- 17. Antitumor Activity, Pharmacology and Clinical Trials of Elliptinium (NSC 264–137).- 18. Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation.- 19. The Role of Cellular Glutathione in Protecting Mammalian Cells from X Radiation and Chemotherapy Agents in vitro.- 20. The Role of Papilloma Viruses in Human Cancer.- 21 Anti-Viral Vaccine Control of EB Virus-Associated Cancers.- 22. Bovine Leukosis Virus as a Model for Human Retroviruses.- 23. Human T-Lymphotropic Retroviruses and their Role in Human Diseases.- 24.Molecular Biology of the Human T-Lymphotropic Retroviruses.- 25. Antiviral Approaches in the Treatment of Acquired Immune Deficiency Syndrome.- 26. Inhibition of HTLV-III Replication in Cell Cultures.- 27. Proteins Encoded by the Human T-Lymphotropic Virus Type III/Lymphadenopathy Associated Virus (HTLV-III/LAV) Genes.- 28. Cytopathogenic Mechanisms which Lead to Cell Death of HTLV-III Infected T. Cells.- 29. Clinical Aspects of Thymic Factors in the Treatment of Immunodeficiency Diseases and Neoplasia: Achievements and Failures.- 30. An Overview of the Current Understanding and Management of the Non-Hodgkin’s Lymphomas.- Participants.